Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Barone

Showing results (381-390 of 399) with videos related to

Pageof 40
Sort By:
Brain Communications|November 20, 2020
Cerebrovascular disease promotes tau pathology in Alzheimer's diseaseKrystal K Laing, Sabrina Simoes, Gloria P Baena-Caldas, et al.
Medicinal Research Reviews|February 27, 2001
Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
Plos Biology|January 22, 2020
A role for triglyceride lipase brummer in the regulation of sex differences in Drosophila fat storage and breakdownLianna W Wat, Charlotte Chao, Rachael Bartlett, et al.
Journal of Translational Medicine|February 14, 2016
First translational 'Think Tank' on cerebrovascular disease, cognitive impairment and dementiaFrank C Barone, Deborah Gustafson, Howard A Crystal, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 19, 2000
Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonistH M Sarau, D E Griswold, B Bush, et al.
Geroscience|July 21, 2025
Advancing clinical trial readiness in white matter disease and related dementias: key steps for future research progressPradoldej Sompol, Gregory A Jicha, Jason D Hinman, et al.
Geroscience|October 4, 2021
Expanding the horizon of research into the pathogenesis of the white matter diseases: Proceedings of the 2021 Annual Workshop of the Albert Research Institute for White Matter and CognitionShawn N Whitehead, Askiel Bruno, Jeffrey M Burns, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2014
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trialF Ciardiello, N Normanno, E Maiello, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2014
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II studyA Necchi, L Mariani, M Di Nicola, et al.
Pageof 40

Showing results (381-390 of 399) with videos related to

Sort By:
Pageof 40
Brain Communications|November 20, 2020
Cerebrovascular disease promotes tau pathology in Alzheimer's diseaseKrystal K Laing, Sabrina Simoes, Gloria P Baena-Caldas, et al.
Medicinal Research Reviews|February 27, 2001
Inhibition of p38 mitogen-activated protein kinase provides neuroprotection in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
Plos Biology|January 22, 2020
A role for triglyceride lipase brummer in the regulation of sex differences in Drosophila fat storage and breakdownLianna W Wat, Charlotte Chao, Rachael Bartlett, et al.
Journal of Translational Medicine|February 14, 2016
First translational 'Think Tank' on cerebrovascular disease, cognitive impairment and dementiaFrank C Barone, Deborah Gustafson, Howard A Crystal, et al.
The Journal of Pharmacology and Experimental Therapeutics|September 19, 2000
Nonpeptide tachykinin receptor antagonists. II. Pharmacological and pharmacokinetic profile of SB-222200, a central nervous system penetrant, potent and selective NK-3 receptor antagonistH M Sarau, D E Griswold, B Bush, et al.
Geroscience|July 21, 2025
Advancing clinical trial readiness in white matter disease and related dementias: key steps for future research progressPradoldej Sompol, Gregory A Jicha, Jason D Hinman, et al.
Geroscience|October 4, 2021
Expanding the horizon of research into the pathogenesis of the white matter diseases: Proceedings of the 2021 Annual Workshop of the Albert Research Institute for White Matter and CognitionShawn N Whitehead, Askiel Bruno, Jeffrey M Burns, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|June 20, 2014
Clinical activity of FOLFIRI plus cetuximab according to extended gene mutation status by next-generation sequencing: findings from the CAPRI-GOIM trialF Ciardiello, N Normanno, E Maiello, et al.
The Journal of Pharmacology and Experimental Therapeutics|February 13, 2001
SB 239063, a second-generation p38 mitogen-activated protein kinase inhibitor, reduces brain injury and neurological deficits in cerebral focal ischemiaF C Barone, E A Irving, A M Ray, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2014
High-dose sequential chemotherapy (HDS) versus PEB chemotherapy as first-line treatment of patients with poor prognosis germ-cell tumors: mature results of an Italian randomized phase II studyA Necchi, L Mariani, M Di Nicola, et al.
Pageof 40